A comparison of sustained-release bupropion and placebo for smokeless tobacco cessation.
OBJECTIVE
To evaluate the potential efficacy of bupropion sustained release when used in combination with minimal counseling for moist snuff cessation in males.


METHODS
A double-blind, placebo-controlled 3-month trial. The active treatment group (n = 35) received bupropion SR at 150 mg/qd day for the first 3 days, then beginning day 4 through day 49 (7 weeks) 150 mg/ b.i.d. The placebo group (n= 35) received 1 tablet qd for 3 days and beginning day 4 through day 49, 1 tablet/b.i.d.


RESULTS
Bupropion 300 mg/day (150 b.i.d.) produced significantly higher quit rates for smokeless tobacco cessation at the end of treatment (7 weeks) than placebo (p = 0.04) with an OR of 2.73.


CONCLUSIONS
Bupropion SR appears to be effective for smokeless tobacco cessation.
Glover
Elbert D
ED
Addiction and Psychiatric Medicine Research, West Virginia University School of Medicine, Morgantown 26506-9135, USA. eglover@hsc.wvu.edu
Glover
Penny N
PN
Sullivan
C Rollynn
CR
Cerullo
Connie L
CL
Hobbs
Gerald
G
D000328:Adult; D000368:Aged; D016642:Bupropion / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D009042:Motivation; D010919:Placebos; D014029:Tobacco Use Disorder / Q000188:drug therapy* / Q000517:prevention & control; D014030:Tobacco, Smokeless; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D018765:Dopamine Uptake Inhibitors; D010919:Placebos; D016642:Bupropion